Table 1 Demographics and clinical characteristics of the patients.
From: Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis
Characteristics | Number (N = 13)/percentage (%) |
|---|---|
Age (years) | |
 Median (range) | 34 (18–79) |
Gender-no. (%) | |
Female | 3 (23) |
Male | 10 (77) |
 Aetiology-no. (%) | 9 (37.5) |
Epstein-Barr virus infection | 5 (38) |
Lymphoma | 5 (38) |
Autoimmune disease | 2 (15) |
Unidentified | 1 (8) |
Onset of HLH symptoms to therapy (weeks) | |
Median (range) | 4.6 (1.7–13.3) |
Regimens towards HLH prior to emapalumab-no. (%) | |
Intravenous glucocorticoids | 5 (38) |
Ruxolitinib | 5 (38) |
Etoposide | 4 (31) |
IVIG | 2 (15) |
Ciclosporin | 1 (8) |
Status of HLH before therapy-no. (%) | |
Initial | 5 (38) |
Refractory | 5 (38) |
Relapse | 3 (23) |
